Abeona Therapeutics Inc. (ABEO) Analysts See $-0.13 EPS

March 5, 2018 - By Peter Erickson

 Abeona Therapeutics Inc. (ABEO) Analysts See $ 0.13 EPS

Analysts expect Abeona Therapeutics Inc. (NASDAQ:ABEO) to report $-0.13 EPS on March, 30.They anticipate $0.06 EPS change or 31.58 % from last quarter’s $-0.19 EPS. After having $-0.13 EPS previously, Abeona Therapeutics Inc.’s analysts see 0.00 % EPS growth. The stock increased 10.71% or $1.5 during the last trading session, reaching $15.5. About 1.38 million shares traded or 31.08% up from the average. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 151.02% since March 5, 2017 and is uptrending. It has outperformed by 134.32% the S&P500.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 36 analyst reports since December 16, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 2 by RBC Capital Markets. The rating was maintained by H.C. Wainwright on Monday, September 18 with “Buy”. Rodman & Renshaw reinitiated Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Wednesday, April 20. Rodman & Renshaw has “Buy” rating and $17 target. Jefferies maintained the shares of ABEO in report on Friday, September 22 with “Buy” rating. The company was maintained on Thursday, October 12 by Cantor Fitzgerald. The firm earned “Buy” rating on Thursday, August 24 by H.C. Wainwright. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Tuesday, August 8 by Cowen & Co. The company was maintained on Wednesday, August 16 by Maxim Group. The firm has “Buy” rating by RBC Capital Markets given on Thursday, September 14. The company was maintained on Tuesday, November 21 by Jefferies.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $725.02 million. The company's lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

More notable recent Abeona Therapeutics Inc. (NASDAQ:ABEO) news were published by: Valuewalk.com which released: “Mox Reports Short Abeona Therapeutics Inc (ABEO) On “Manipulated Trial Data”” on February 15, 2018, also Globenewswire.com with their article: “Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene …” published on February 12, 2018, Seekingalpha.com published: “This ROTY Contender Just Released Promising Data” on February 08, 2018. More interesting news about Abeona Therapeutics Inc. (NASDAQ:ABEO) were released by: Seekingalpha.com and their article: “Abeona Therapeutics: Data Update – Part 2” published on February 12, 2018 as well as Globenewswire.com‘s news article titled: “Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in …” with publication date: February 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.